Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.…
Nyxoah Obtains Default Decision Against Inspire Medical Systems in Unified Patent Court Case
Nyxoah (NASDAQ: NYXH) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 153 employees.
The shares were at 0.8050 USD on 20 November 2026, down 86.3% over 52 weeks. Its 52-week range is 0.8000 USD to 5.860 USD, and it trades at the bottom of that range.
Its market capitalisation is 81.98M USD.
Nyxoah reports return on equity of -183.4%, an operating margin of -282.5% and revenue up 365.0% year over year.
It holds more cash than debt, a net cash position of 23.22M EUR. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 3 analysts cover the stock, with an average rating of Buy; their mean price target of 2.786 USD is 246.1% above the current price. The next earnings report is expected on 18 March 2027.